How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention

医学 胆固醇 图书馆学 内科学 家庭医学 老年学 计算机科学
作者
Fatima Rodriguez,Amit Khera
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:147 (16): 1204-1207
标识
DOI:10.1161/circulationaha.123.064041
摘要

HomeCirculationVol. 147, No. 16How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextHow Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention Fatima Rodriguez and Amit Khera Fatima RodriguezFatima Rodriguez https://orcid.org/0000-0002-5226-0723 Department of Internal Medicine, Division of Cardiology and the Cardiovascular Institute, Stanford University, CA (F.A.). Search for more papers by this author and Amit KheraAmit Khera Correspondence to: Amit Khera, MD, MSc, Division of Cardiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8830. Email E-mail Address: [email protected] https://orcid.org/0000-0001-7255-6874 Department of Internal Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX (A.K.). Search for more papers by this author Originally published17 Apr 2023https://doi.org/10.1161/CIRCULATIONAHA.123.064041Circulation. 2023;147:1204–1207This article is a commentary on the followingAssociation Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLEFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1207.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Amit Khera, MD, MSc, Division of Cardiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8830. Email amit.[email protected]eduReferences1. Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects.JAMA. 1998; 280:2099–2104. doi: 10.1001/jama.280.24.2099CrossrefMedlineGoogle Scholar2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019; 139:e1082–e1143. doi: 10.1161/CIR.0000000000000625LinkGoogle Scholar3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020; 41:111–188. doi: 10.1093/eurheartj/ehz455CrossrefMedlineGoogle Scholar4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet. 2005; 366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1CrossrefMedlineGoogle Scholar5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344:1383–1389.MedlineGoogle Scholar6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators.N Engl J Med. 1996; 335:1001–1009. doi: 10.1056/NEJM199610033351401CrossrefMedlineGoogle Scholar7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med. 2004; 350:1495–1504. doi: 10.1056/NEJMoa040583CrossrefMedlineGoogle Scholar8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med. 2015; 372:2387–2397. doi: 10.1056/NEJMoa1410489CrossrefMedlineGoogle Scholar9. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med. 2017; 376:1713–1722. doi: 10.1056/NEJMoa1615664CrossrefMedlineGoogle Scholar10. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med. 2018; 379:2097–2107. doi: 10.1056/NEJMoa1801174CrossrefMedlineGoogle Scholar11. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.Lancet. 2017; 390:1962–1971. doi: 10.1016/S0140-6736(17)32290-0CrossrefMedlineGoogle Scholar12. Gaba P, O’Donoghue ML, Park J-G, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE.Circulation. 2023; 147:1192–1203. doi: 10.1161/CIRCULATIONAHA.122.063399LinkGoogle Scholar13. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial.JAMA Cardiol. 2017; 2:547–555. doi: 10.1001/jamacardio.2017.0083CrossrefMedlineGoogle Scholar14. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC, Waring AA, et al; Writing Committee. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol. 2022; 80:1366–1418. doi: 10.1016/j.jacc.2022.07.006CrossrefMedlineGoogle Scholar15. Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, et al. Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER trial.JAMA Cardiol. 2018; 3:749–753. doi: 10.1001/jamacardio.2018.1533CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesAssociation Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLEPrakriti Gaba, et al. Circulation. 2023;147:1192-1203 April 18, 2023Vol 147, Issue 16 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.064041PMID: 37068134 Originally publishedApril 17, 2023 KeywordsEditorialsPDF download Advertisement SubjectsLipids and CholesterolRisk Factors
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
文艺明杰完成签到,获得积分10
1秒前
六个核桃发布了新的文献求助10
1秒前
1秒前
2秒前
浮名半生发布了新的文献求助10
3秒前
学术大白发布了新的文献求助10
4秒前
77发布了新的文献求助10
4秒前
科研通AI2S应助海绵宝宝采纳,获得10
5秒前
TTTT发布了新的文献求助10
6秒前
CodeCraft应助pear采纳,获得10
6秒前
慢歌完成签到 ,获得积分10
7秒前
ytx完成签到,获得积分20
7秒前
保持理智完成签到,获得积分10
8秒前
蔚蓝绽放完成签到,获得积分10
10秒前
我是老大应助xiaowen采纳,获得10
11秒前
烟花应助好好毕业采纳,获得10
11秒前
Singularity发布了新的文献求助10
12秒前
Ganlou应助暖粥采纳,获得10
12秒前
听诊器完成签到 ,获得积分10
14秒前
15秒前
15秒前
77完成签到,获得积分10
15秒前
烟花应助小旋风采纳,获得10
16秒前
华仔应助ytx采纳,获得10
16秒前
17秒前
Chenbiao发布了新的文献求助10
20秒前
20秒前
20秒前
李健应助zzuwxj采纳,获得10
21秒前
李健应助gdh采纳,获得10
22秒前
伯约的麒麟完成签到,获得积分10
22秒前
pear发布了新的文献求助10
22秒前
23秒前
微笑亿先发布了新的文献求助10
23秒前
桐桐应助guo采纳,获得10
23秒前
科研疯狗发布了新的文献求助10
23秒前
wodel完成签到,获得积分10
24秒前
yar应助Y-L采纳,获得10
24秒前
了解驳回了Jasper应助
25秒前
26秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Introduction to Spectroscopic Ellipsometry of Thin Film Materials Instrumentation, Data Analysis, and Applications 600
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
Shining Light on the Dark Side of Personality 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3308738
求助须知:如何正确求助?哪些是违规求助? 2942021
关于积分的说明 8507135
捐赠科研通 2617034
什么是DOI,文献DOI怎么找? 1429940
科研通“疑难数据库(出版商)”最低求助积分说明 663969
邀请新用户注册赠送积分活动 649160